This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 1
  • /
  • FDA acceptance of sNDA for Ayvakit for the treatme...
News

FDA acceptance of sNDA for Ayvakit for the treatment of indolent systemic mastocytosis

Read time: 1 mins
Published:24th Jan 2023

Blueprint Medicines Corporation announced that the FDA has accepted the company's supplemental new drug application for Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM)

The FDA granted priority review with an action date of May 22, 2023 under the Prescription Drug User Fee Act (PDUFA).

This regulatory application is based on results from the global PIONEER trial, the largest randomized, placebo-controlled study ever conducted in indolent SM. The FDA previously granted breakthrough therapy designation to Ayvakit for the treatment of moderate to severe indolent SM. Ayvakit was designed to potently and selectively inhibit D816V mutant KIT, the primary underlying cause of SM.

Ayvakit was designed to potently and selectively inhibit D816V mutant KIT, the primary underlying cause of SM.

Condition: Systemic Mastocytosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.